Journal
BIOMATERIALS
Volume 224, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2019.119490
Keywords
Thermal ablation therapy; Imiquimod; Immune checkpoint blockade; Cancer immunotherapy
Funding
- National Basic Research Programs of China [2016YFA0201200]
- National Natural Science Foundation of China [51525203, 51803146, 81771850]
- Joint International Research Laboratory of Carbon-Based Functional Materials and Devices
- Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions
- Soochow University
- Program for Jiangsu Specially-Appointed Professors
- Collaborative Innovation Center of Suzhou Nano Science and Technology
Ask authors/readers for more resources
Tumor ablation therapies provide a minimally invasive approach to treat cancer. However, inhibition of cancer metastasis and recurrence after ablation is still a challenge in clinical trials. Here, we propose a strategy using combinatorial thermal ablation, adjuvants and immune checkpoint blockade (ICB) to inhibit metastatic tumor and recurrence via antitumor immune responses post tumor thermal ablation, which are frequently used in the clinic. Furthermore, a strong immune memory against cancer was observed 80 days after the primary tumor was ablated. Considering that all components in our design are approved by Food and Drug Administration (FDA), we provide a strategy based on clinically used cancer treatment technique that is promising in clinical translation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available